Winner-Badge 1a.png


Emepelle is a revolutionary advanced innovation that was formulated to rejuvenate and restore the affected skin post-menopause. Being one and only cosmeceutical to feature MEP Technology®, it is clinically proven to reinvigorate the natural functions of skin effectively and safely, targeting the root cause of ageing in skin affected by menopause.

MEP technology is an advanced non-hormonal oestrogen receptor that stimulates restoring the loss of collagen, thickness, and hyaluronic acid in the skin that is affected by menopause.

While other skin care products help improve visible signs of aging, Emepelle is the technology that addresses the cause of aging and restores the natural radiance our skin loses over time. Along with taking antioxidants regularly, it is important to follow a skincare routine, eat healthily, and whatnot- you still won’t get the best results. This occurs because of missing the estrogen factor due to menopause or peri-menopause. Bringing Emepelle into your daily skincare and wellness routine, you will provide your skin with an effective and safe solution that is clinically proven to help improve your skin. 

Since it is not a hormone and is free from oestrogen, it works only on skin cells to activate and promote new oestrogen receptors. Combining the brilliant MEP technology with a synergistic blend of cosmeceutical ingredients. This advanced technology helps rejuvenate, re-balance, and restore skin affected by menopause.

The Emepelle regime entails Emepelle serum and Emepelle Night Cream that help restore the radiance of your skin- with no need for multiple skincare products. 

Before & After


A double-blind randomized pilot study evaluating the safety and efficacy of topical MEP in the facial appearance improvement of estrogen deficient females. By Zoe Diana Draelos. Journal of Drugs Dermatology. 2018;17(11):1032-1035. Read Full Text.

Evaluation of Efficacy of a Skin Care Regimen Containing Methyl Estradiolpropanoate (MEP) for Treating Estrogen Deficient Skin. By Joel L. Cohen. Journal of Drugs Dermatology. 2019 Dec 1;18(12):1226-1230.

Read Full Text.

Clinical studies & research